106 related articles for article (PubMed ID: 1457361)
1. Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
Janssen RA; Sleijfer DT; Heijn AA; Mulder NH; The TH; de Leij L
Br J Cancer; 1992 Dec; 66(6):1177-9. PubMed ID: 1457361
[TBL] [Abstract][Full Text] [Related]
2. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
3. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
[TBL] [Abstract][Full Text] [Related]
4. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
5. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
7. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
[TBL] [Abstract][Full Text] [Related]
8. Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival.
Jeong IG; Han KS; Joung JY; Choi WS; Hwang SS; Yang SO; Seo HK; Chung J; Lee KH
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S122-8. PubMed ID: 17923738
[TBL] [Abstract][Full Text] [Related]
9. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of recombinant interleukin-2 for renal cell carcinoma and the effect of blood transfusion upon the immune response of these patients].
Fujioka T; Kudo T; Ishikura K; Shiraishi M; Tanji S; Okamoto T; Suzuki K; Koike H; Kumagai K; Ohhori T
Nihon Hinyokika Gakkai Zasshi; 1990 Feb; 81(2):296-303. PubMed ID: 2325327
[TBL] [Abstract][Full Text] [Related]
11. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
[TBL] [Abstract][Full Text] [Related]
12. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
13. Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidence.
Capelli E; Barni S; Vaccarone R; Fortis C; Nano R
Anticancer Res; 1996; 16(4A):1775-80. PubMed ID: 8712700
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural changes of neutrophils following IL-2 treatment in vivo.
Nano R; Capelli E; Barni S; Gerzeli G
Ann N Y Acad Sci; 1997 Dec; 832():194-9. PubMed ID: 9704047
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary findings on clinical and immunological effects of subcutaneously administered interleukin-2 + alpha-interferon combination in the treatment of advanced renal carcinoma].
Buda F; Buda C; Croatto T; Costa B; Aragona P; Tuveri G
Recenti Prog Med; 1995; 86(7-8):304-5. PubMed ID: 7569288
[No Abstract] [Full Text] [Related]
18. Prolonged continuous infusion of low-dose rIL-2.
Janssen RA; Buter J; The TH; Mulder NH; de Leij L
Br J Cancer; 1994 May; 69(5):976-7. PubMed ID: 8180034
[No Abstract] [Full Text] [Related]
19. Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma.
Marumo K; Muraki J; Ueno M; Tachibana M; Deguchi N; Baba S; Jitsukawa S; Hata M; Tazaki H
Urology; 1989 Mar; 33(3):219-25. PubMed ID: 2784018
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
